The integrase inhibitor raltegravir continues to show strong efficacy "almost identical" to that of efavirenz at 96 weeks, in combination with tenofovir and 3TC, and a side-effect profile that continues to be favourable, Dr Marty Markowitz of the Aaron Diamond AIDS Research Center reported at the XVII International AIDS Conference in Mexico City.
Raltegravir is an integrase inhibitor currently being studied in both treatment-experienced and in treatment-naive patients. Owing to its significant and durable effects in highly treatment-experienced patients, raltegravir (Isentress) has already received approval in Australia and is availabale under the Pharmaceutical Benefits Scheme.
http://www.aidsmap.org/en/news/82A67A30-B689-46D7-9BAB-2DE43B46AA8C.asp